Agnes B. Fogo
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Previous Organizations / Institutes
The organizations / institutes from the scholar's other articles in the past ten years
Research Subjects
Research Interests
Agnes B. Fogo has a total of 20 co-authors. Here are the top co-authors by number of shared publications:
Paisit Paueksakon
Department of Pathology, Vanderbilt University Medical Center, Nashville, Tennessee 37232, USA
4 shared publicationsMonica P. Revelo
Vanderbilt University Medical Center
2 shared publicationsCarmelita Marcantoni
Vanderbilt University Medical Center
1 shared publicationDaping Fan
1 shared publication- Douglas E. Vaughan
Northwestern University Feinberg School of Medicine, Chicago, Illinois, USA
1 shared publication - Hagai Tavori
Knight Cardiovascular Institute, Center for Preventive Cardiology, Oregon Health and Science University, Portland, OR, USA
1 shared publication
Latest Publications
- 1 March 2014
- Published by Elsevier in Atherosclerosis
- Vol. 233 (1) , 327
Expression of apoESendai by macrophages causes lipoprotein glomerulopathy while suppressing atherosclerosis
- 1 March 2014
- Published by Elsevier in Atherosclerosis
- Vol. 233 (1) , 327
Expression of apoESendai by macrophages causes lipoprotein glomerulopathy while suppressing atherosclerosis
- 1 February 2003
- Published by Elsevier in Kidney International
- Vol. 63 (83) , S17-S21
Hypertensive risk factors in kidney disease in African Americans
- 1 February 2003
- Published by Elsevier in Kidney International
- Vol. 63 (83) , S17-S21
Hypertensive risk factors in kidney disease in African Americans
- 13 July 2002
- Vol. 15 (3) , 230-5
Aldosterone and PAI-1: implications for renal injury.
Aldosterone modulates cardiovascular and renal injury and fibrosis in animal models. This review explores the hypothesis that aldosterone causes injury and fibrosis, in part, through effects on plasminogen activator inhibitor-1, the major physiological inhibitor of plasminogen activators in vivo. Aldosterone interacts with angiotensin II to increase plasminogen activator inhibitor-1 expression in vitro and in vivo. Plasminogen activator inhibitor-1, by inhibiting the production of plasmin from plasminogen, tips the balance in favor of extracellular matrix accumulation and promotes fibrosis. Aldosterone receptor antagonism decreases both PAI-1 expression and fibrosis in animal models. These findings have implications for the clinical management of cardiovascular and renal disease.
- 13 July 2002
- Vol. 15 (3) , 230-5
Aldosterone and PAI-1: implications for renal injury.
Aldosterone modulates cardiovascular and renal injury and fibrosis in animal models. This review explores the hypothesis that aldosterone causes injury and fibrosis, in part, through effects on plasminogen activator inhibitor-1, the major physiological inhibitor of plasminogen activators in vivo. Aldosterone interacts with angiotensin II to increase plasminogen activator inhibitor-1 expression in vitro and in vivo. Plasminogen activator inhibitor-1, by inhibiting the production of plasmin from plasminogen, tips the balance in favor of extracellular matrix accumulation and promotes fibrosis. Aldosterone receptor antagonism decreases both PAI-1 expression and fibrosis in animal models. These findings have implications for the clinical management of cardiovascular and renal disease.
- 1 June 2002
- Published by Elsevier in Kidney International
- Vol. 61 (6) , 2142-2148
Microangiopathic injury and augmented PAI-1 in human diabetic nephropathy
- 1 June 2002
- Published by Elsevier in Kidney International
- Vol. 61 (6) , 2142-2148
Microangiopathic injury and augmented PAI-1 in human diabetic nephropathy
- 1 June 2002
- Published by Elsevier in Kidney International
- Vol. 61 (6) , 2274-2275
Diabetic nephropathy: It's in the numbers
- 1 June 2002
- Published by Elsevier in Kidney International
- Vol. 61 (6) , 2274-2275
Diabetic nephropathy: It's in the numbers
- 19 January 2002
- p. S63-9
Mechanisms in nephrosclerosis and hypertension-beyond hemodynamics.
These studies support that global glomerulosclerosis is a key lesion in human hypertensive nephrosclerosis, and cannot be simply explained by worse vascular sclerosis caused by higher blood pressure. Possible pathogenetic mechanisms include genetic susceptibility, accelerated aging and a primary microvascular disease. The potential importance of the renin angiotensin system in glomerular sclerosis is underscored by the effectiveness of therapies that aim to inhibit its manifold actions, including induction of plasminogen activator inhibitor-1 (PAI-1). Further, regression of existing glomerulosclerosis, including age-related renal and vascular sclerosis, can be achieved in various experimental settings by high dose angiotensin inhibiton, and is linked to inhibition of PAI-1. Ongoing studies will establish which of these provocative findings from animal models are relevant to human diseases, and may lead to optimal therapies to forestall progression and perhaps even induce regression of sclerosis.
- 19 January 2002
- p. S63-9
Mechanisms in nephrosclerosis and hypertension-beyond hemodynamics.
These studies support that global glomerulosclerosis is a key lesion in human hypertensive nephrosclerosis, and cannot be simply explained by worse vascular sclerosis caused by higher blood pressure. Possible pathogenetic mechanisms include genetic susceptibility, accelerated aging and a primary microvascular disease. The potential importance of the renin angiotensin system in glomerular sclerosis is underscored by the effectiveness of therapies that aim to inhibit its manifold actions, including induction of plasminogen activator inhibitor-1 (PAI-1). Further, regression of existing glomerulosclerosis, including age-related renal and vascular sclerosis, can be achieved in various experimental settings by high dose angiotensin inhibiton, and is linked to inhibition of PAI-1. Ongoing studies will establish which of these provocative findings from animal models are relevant to human diseases, and may lead to optimal therapies to forestall progression and perhaps even induce regression of sclerosis.
- 1 October 2000
- Published by Elsevier in American Journal of Kidney Diseases
- Vol. 36 (4) , 871-874
A 14-year-old boy with kidney allograft failure in the first month after transplantation.
- 1 October 2000
- Published by Elsevier in American Journal of Kidney Diseases
- Vol. 36 (4) , 871-874
A 14-year-old boy with kidney allograft failure in the first month after transplantation.
- 1 May 2000
- Published by Wolters Kluwer Health in Current Opinion in Nephrology and Hypertension
- Vol. 9 (3) , 241-246
Pathology of progressive nephropathies
The role of cell cycle regulatory proteins in progression is elucidated. Human renal biopsy data show amelioration and even regression of structural injury with interventions. Data implicate new mechanisms of the renin-aldosterone-angiotensin system in progressive injuries, including immune modulation and a direct effect of aldosterone on progression. New approaches and interventions that target these fibrotic responses show promising results.
- 1 May 2000
- Published by Wolters Kluwer Health in Current Opinion in Nephrology and Hypertension
- Vol. 9 (3) , 241-246
Pathology of progressive nephropathies
The role of cell cycle regulatory proteins in progression is elucidated. Human renal biopsy data show amelioration and even regression of structural injury with interventions. Data implicate new mechanisms of the renin-aldosterone-angiotensin system in progressive injuries, including immune modulation and a direct effect of aldosterone on progression. New approaches and interventions that target these fibrotic responses show promising results.
- 21 April 2000
- Published by S. Karger AG in Nephron
- Vol. 85 (1) , 8-13
Nephrotic Syndrome: Molecular and Genetic Basis
Nephrotic syndrome results from varying injuries to the capillary wall of the glomerulus. The components of the capillary wall, including the endothelial cell, glomerular basement membrane and glomerular visceral epithelial cell all may be targets of injury and contribute to proteinuria. These mechanisms of injury include immune complexes, cytotoxins, abnormal protein deposition, metabolic abnormalities, reactive oxygen species, growth factors, hemodynamic stress, and genetic abnormalities. We review mechanisms of glomerular permselectivity, with focus on emerging new understanding of the functions of the glomerular visceral epithelial cell. The significance and consequences of proteinuria and possible pathogenic mechanisms and the effect of interventions in clinical renal disease on these factors are considered.
- 21 April 2000
- Published by S. Karger AG in Nephron
- Vol. 85 (1) , 8-13
Nephrotic Syndrome: Molecular and Genetic Basis
Nephrotic syndrome results from varying injuries to the capillary wall of the glomerulus. The components of the capillary wall, including the endothelial cell, glomerular basement membrane and glomerular visceral epithelial cell all may be targets of injury and contribute to proteinuria. These mechanisms of injury include immune complexes, cytotoxins, abnormal protein deposition, metabolic abnormalities, reactive oxygen species, growth factors, hemodynamic stress, and genetic abnormalities. We review mechanisms of glomerular permselectivity, with focus on emerging new understanding of the functions of the glomerular visceral epithelial cell. The significance and consequences of proteinuria and possible pathogenic mechanisms and the effect of interventions in clinical renal disease on these factors are considered.
- 1 April 2000
- Vol. 75, S15-21
Glomerular hypertension, abnormal glomerular growth, and progression of renal diseases.
The development and progression of sclerosis is determined by complex interactions of many mechanisms, including direct hemodynamic actions, modulation of glomerular cell injury, and growth factor actions. The interplay of these factors determines the balance of cell growth and proliferation versus cell death by necrosis or apoptosis, and the balance of matrix accumulation versus degradation. Sclerosis may even be reversed when therapies inhibit these mechanisms and augment matrix degradation processes, both by directly increasing proteolytic activity and by down-regulating inhibitors of matrix degradation. We will focus in this review on the roles of glomerular hemodynamics and growth in the progression of renal diseases.
- 1 April 2000
- Vol. 75, S15-21
Glomerular hypertension, abnormal glomerular growth, and progression of renal diseases.
The development and progression of sclerosis is determined by complex interactions of many mechanisms, including direct hemodynamic actions, modulation of glomerular cell injury, and growth factor actions. The interplay of these factors determines the balance of cell growth and proliferation versus cell death by necrosis or apoptosis, and the balance of matrix accumulation versus degradation. Sclerosis may even be reversed when therapies inhibit these mechanisms and augment matrix degradation processes, both by directly increasing proteolytic activity and by down-regulating inhibitors of matrix degradation. We will focus in this review on the roles of glomerular hemodynamics and growth in the progression of renal diseases.